| 注册
首页|期刊导航|中国临床药学杂志|他达拉非片在中国健康受试者体内的生物等效性及药动学研究

他达拉非片在中国健康受试者体内的生物等效性及药动学研究

洪亦超 庞锦萍 张亮 胡林水 石芮凡 黄小梅 任雲鹏 胡江宁

中国临床药学杂志2026,Vol.35Issue(4):329-335,7.
✕
中国临床药学杂志2026,Vol.35Issue(4):329-335,7.DOI:10.19577/j.1007-4406.2026.04.007

他达拉非片在中国健康受试者体内的生物等效性及药动学研究

Bioequivalence and pharmacokinetic study of tadalafil tablets in healthy Chinese subjects

洪亦超 1庞锦萍 1张亮 1胡林水 1石芮凡 1黄小梅 2任雲鹏 1胡江宁1

作者信息

  • 1. 浙江康恩贝制药股份有限公司,杭州 310052
  • 2. 湘雅博爱康复医院Ⅰ期临床研究室,长沙 410029
  • 折叠

摘要

Abstract

AIM To evaluate the bioequivalence,pharmacokinetics,and safety of 2 tadalafil tablets in healthy Chinese subjects.METHODS A single-center,randomized,open,two-period,self-crossover trial was designed with 24 healthy subjects in the fasted and fed groups.For each group,a single oral dose of 20 mg was administered per period for both the test and reference formulations.The concentration of tadalafil in plasma at multiple time points following administration was measured by liquid chromatography tandem mass spectrometry(LC-MS/MS).WinNonlin 8.3 was used to conduct the non-compartmental analysis for pharmacokinetic(PK)parameters.SAS 9.4 software was used to perform analysis of variance(ANOVA)on the log-transformed Cmax and AUC of the test and reference formulations.The geometric mean ratios and their 90%confidence intervals were calculated for bioequivalence comparison,with the equivalence interval set at 80.00%to 125.00%.Safety was assessed by the incidence of adverse events(AEs).RESULTS The main PK parameters of tadalafil in the fasted group for the test and reference formulations were as follows:Cmax were(382.12±108.00)μg·L-1 and(372.04±88.54)μg·L-1;AUC0-t were(9 913.95±3 663.76)μg·h·L-1 and(9 895.98±3 944.39)μg·h·L-1;AUC0-∞ were(10 176.21±3 661.42)μg·h·L-1 and(10 079.40±3 825.68)μg·h·L-1.The main PK parameters of tadalafil in the fed group for the test formulation and reference formulation were as follows:Cmax were(515.29±86.36)μg·L-1 and(501.43±100.30)μg·L-1;AUC0-t were(11 713.21±2 954.11)μg·h·L-1 and(11 794.72±4 187.48)μg·h·L-1;AUC0-∞ were(12 552.20±3 619.53)μg·h·L-1 and(12 723.88±5 047.66)μg·h·L-1.The 90%confidence intervals for the Cmax,AUC0-t and AUC0-∞ were all within the equivalence interval of 80%-125%for both the test and reference formulations.Both formulations demonstrated bioequivalence.No serious adverse events occurred across any groups.CONCLUSION The 2 tadalafil tablets demonstrate bioequivalence under both fasted and fed conditions and exhibit good safety profiles.

关键词

他达拉非/生物等效性/药动学

Key words

tadalafil/bioequivalence/pharmacokinetics

分类

医药卫生

引用本文复制引用

洪亦超,庞锦萍,张亮,胡林水,石芮凡,黄小梅,任雲鹏,胡江宁..他达拉非片在中国健康受试者体内的生物等效性及药动学研究[J].中国临床药学杂志,2026,35(4):329-335,7.

中国临床药学杂志

1007-4406

访问量0
|
下载量0
段落导航相关论文